Susan G. Panzer‐Knodle

Author

Also Known As

S G Panzer-Knodle, S Panzer-Knodle, S. G. Panzer-Knodle, S. Panzer-Knodle, S.G. Panzer-Knodle, SUSAN G. PANZER‐KNODLE, Susan G Panzer-Knodle, Susan G. Panzer-Knodle, Susan G. Panzer‐Knodle, Susan Panzer-Knodle

Publications

672

Citations

H-Index

Concepts

All Affiliations

Monsanto (United States)Sears Holdings (United States)Portland Cement Association Knowledge Systems Institute

About

Susan G. Panzer‐Knodle is an author at Monsanto (United States) specializing in medicine, thrombosis, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	299
2	Natural Sciences	2	2	148
3	Biochemistry	2	2	148
4	Biomedical Engineering	1	1	14
5	Chemical Biology	1	1	41

Susan G. Panzer‐Knodle

Publications

484

Citations

H-Index

Page 1

	Year	Citations
Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor Jeffery A. Zablocki, Masateru Miyano, Robert B. Garland, Journal of Medicinal Chemistry Pharmaceutical SciencePharmacotherapyRgdx MimeticsPlatelet AggregationThrombosis	1993	107
SC-54684A: An Orally Active Inhibitor of Platelet Aggregation Nancy S. Nicholson, Susan G. Panzer‐Knodle, Anita K. Salyers, Circulation	1995	65
A New Model of Dual Interacting Ligand Binding Sites on Integrin αIIbβ3 Dana D. Hu, Carol A. White, Susan G. Panzer‐Knodle, Journal of Biological Chemistry	1999	60
Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor Jeffery A. Zablocki, Masateru Miyano, Shashidhar N. Rao, Journal of Medicinal Chemistry Altmetric Attention ScorePharmacotherapyRgdx MimeticsChemical BiologyPlatelet Aggregation	1992	41
In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent Nancy S. Nicholson, Susan G. Panzer‐Knodle, Anita K. Salyers, Thrombosis Research InflammationThrombosisThrombopoiesisBlood PlateletMedicine	1991	40
Administration of a small molecule tissue factor/Factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time James A. Szalony, Osman D. Suleymanov, Anita K. Salyers, Thrombosis Research ThrombopoiesisThrombosisVenous ThrombosisBleeding TimeMedicine	2003	37
A novel series of orally active antiplatelet agents Jeffery A. Zablocki, Foe S. Tjoeng, Philippe R. Bovy, Bioorganic & Medicinal Chemistry ThrombopoiesisThrombosisPlatelet Aggregation InhibitorsBlood PlateletMedicine	1995	32
Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist Nancy S. Nicholson, Norman Abood, Susan G. Panzer‐Knodle, Medicinal Research Reviews	2001	26
Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749). Nancy S. Nicholson, Susan G. Panzer‐Knodle, Anita K. Salyers, Journal of Pharmacology and Experimental Therapeutics	1990	18
Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation Susan G. Panzer‐Knodle, Beatrice B. Taite, Devan V. Mehrotra, Journal of Pharmacological and Toxicological Methods ThrombopoiesisThrombosisPlatelet Aggregation InhibitorsGlycoprotein Iib/iiiaBlood Platelet	1993	17

Page 1